Streetbeat News

Price Targets

CVS

Analysts have provided mixed ratings on CVS Health (NYSE:CVS) over the past three months, with most maintaining a neutral stance. The average 12-month price target is $62.27, with a slight decrease in sentiment. CVS Health's financial metrics show strong profitability and effective asset utilization, but revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

BDX

Analysts have varied opinions on Becton Dickinson (NYSE:BDX), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $270.0, with a high of $280.00 and a low of $255.00. Analysts have adjusted their ratings and price targets based on market conditions and company performance. Becton Dickinson is a major player in the medical surgical products industry, with strong revenue growth and net margins but challenges in ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

CLX

Clorox (NYSE:CLX) has received mixed analyst ratings over the past three months, with a recent average price target of $148.15, slightly down from $149.17. Analysts have adjusted their ratings and price targets, reflecting varied expectations for Clorox's performance. Despite a decline in revenue growth, Clorox maintains strong financial metrics such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

FSLY

Analysts have recently adjusted their ratings and price targets for Fastly (NYSE:FSLY), reflecting a more cautious outlook. The average 12-month price target has decreased significantly, indicating a shift in sentiment. Fastly's financial health shows positive revenue growth but challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

SBRA

Wells Fargo analyst John Kilichowski has assumed coverage of Sabra Health Care REIT with an Overweight rating and increased the price target to $20.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:58 pm

CVS

Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on CVS Health and maintained a $62 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:55 pm

NHI

Wells Fargo analyst John Kilichowski has assumed coverage of National Health Investors (NYSE:NHI) with an Equal-Weight rating and has raised the price target to $86.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:55 pm

CNC

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Centene (NYSE:CNC) and maintained a $90 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:53 pm

CI

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Cigna (NYSE:CI) and maintained a $400 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:51 pm

CCL

Carnival Corporation (NYSE:CCL) shares are trading lower after the company reported its third-quarter earnings and issued weaker-than-expected guidance for the fourth quarter. Despite beating third-quarter expectations, Carnival's forecast of 5 cents per share for the fourth quarter fell short of the consensus estimate of 7 cents. Analysts have mixed ratings, with Mizuho maintaining an Outperform rating and raising the price target to $26, while Morgan Stanley maintained an Underweight rating but increased the price target to $16.50. The stock is down 4.25% at $17.70 as investors digest the news.

Portfolio Pulse from Erica Kollmann

October 01, 2024 | 2:49 pm